Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec 200 U/mL vs Insulin Glargine in Type 2 Diabetes
NCT01570751Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2012
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Apr 2012; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01570751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570751.